MX2021012277A - Agonista multireceptor y uso medico del mismo. - Google Patents
Agonista multireceptor y uso medico del mismo.Info
- Publication number
- MX2021012277A MX2021012277A MX2021012277A MX2021012277A MX2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- receptor agonist
- medical use
- glp
- insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una serie de composiciones farmacéuticas que contienen compuestos agonistas duales de polipéptidos y sales farmacéuticamente aceptables de los mismos, en donde los mismos tienen efectos agonistas duales en un receptor de péptido similar a glucagón tipo 1 (GLP-1) humano y un receptor de polipéptido insulinotrópico dependiente de glucosa (GIP) de sangre humana, y se pueden utilizar para tratar diabetes no dependiente de insulina, diabetes insulinodependiente, obesidad y otras enfermedades relacionadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910290162 | 2019-04-11 | ||
CN201911120906 | 2019-11-15 | ||
PCT/CN2020/084247 WO2020207477A1 (zh) | 2019-04-11 | 2020-04-10 | Glp-1和gip受体双重激动剂化合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012277A true MX2021012277A (es) | 2021-11-12 |
Family
ID=72752204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012277A MX2021012277A (es) | 2019-04-11 | 2020-04-10 | Agonista multireceptor y uso medico del mismo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220168396A1 (es) |
EP (1) | EP3954701A4 (es) |
JP (1) | JP7577678B2 (es) |
KR (1) | KR20210149747A (es) |
CN (1) | CN112351994B (es) |
AU (1) | AU2020256648A1 (es) |
BR (1) | BR112021020071A2 (es) |
CA (1) | CA3136163A1 (es) |
MX (1) | MX2021012277A (es) |
TW (1) | TW202104253A (es) |
WO (1) | WO2020207477A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230018395A (ko) * | 2020-05-29 | 2023-02-07 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | Glp-1 및 gip 수용체 둘 모두에 대한 이중 작용제 화합물 및 이의 적용 |
MX2023000303A (es) * | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
KR20230083294A (ko) | 2020-09-30 | 2023-06-09 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩타이드 접합체 및 사용 방법 |
CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
WO2022199629A1 (zh) * | 2021-03-25 | 2022-09-29 | 博瑞生物医药(苏州)股份有限公司 | Gip和glp-1的双受体激动剂、药物组合物及用途 |
US20240150425A1 (en) * | 2021-03-25 | 2024-05-09 | Brightgene Bio-Medical Technology Co., Ltd. | Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use |
JP2024522196A (ja) * | 2021-06-09 | 2024-06-11 | ザ スクリプス リサーチ インスティテュート | 長時間作用型デュアルgip/glp-1ペプチドコンジュゲートおよび使用方法 |
CN115521368B (zh) * | 2021-06-25 | 2024-08-23 | 江苏鸿永医药技术有限公司 | 毒蜥外泌肽-4衍生物 |
KR20240109258A (ko) * | 2021-11-12 | 2024-07-10 | 푸지엔 셩디 파마슈티컬 컴파니 리미티드 | Glp-1 수용체와 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도 |
AU2022401780A1 (en) * | 2021-12-01 | 2024-07-04 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
CN116023444B (zh) * | 2022-08-12 | 2023-08-01 | 重庆宸安生物制药有限公司 | 一种gip和glp-1双受体激动剂多肽化合物及其应用 |
TW202412835A (zh) * | 2022-09-23 | 2024-04-01 | 大陸商博瑞生物醫藥(蘇州)股份有限公司 | 一種glp-1和gip雙受體激動劑藥物組合物及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
NZ589847A (en) | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
WO2010142665A1 (en) * | 2009-06-11 | 2010-12-16 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
PE20120914A1 (es) | 2009-06-16 | 2012-08-22 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip |
CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
EP2654773B1 (en) | 2010-12-22 | 2018-10-03 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
DK2694095T3 (en) * | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
SG11201407137PA (en) * | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
CN103861089B (zh) * | 2012-12-17 | 2019-06-28 | 江苏豪森药业集团有限公司 | Glp-1类似物的衍生物或其可药用盐注射液及其制备方法和用途 |
EP3400957A1 (en) * | 2012-12-21 | 2018-11-14 | Sanofi | Functionalized exendin-4 derivatives |
CN106029087A (zh) * | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
MA49116A (fr) | 2016-12-16 | 2020-03-25 | Novo Nordisk As | Compositions pharmaceutiques contenant de l'insuline |
-
2020
- 2020-04-10 BR BR112021020071A patent/BR112021020071A2/pt unknown
- 2020-04-10 CA CA3136163A patent/CA3136163A1/en active Pending
- 2020-04-10 CN CN202080002789.8A patent/CN112351994B/zh active Active
- 2020-04-10 AU AU2020256648A patent/AU2020256648A1/en active Pending
- 2020-04-10 US US17/594,259 patent/US20220168396A1/en active Pending
- 2020-04-10 MX MX2021012277A patent/MX2021012277A/es unknown
- 2020-04-10 EP EP20786794.6A patent/EP3954701A4/en active Pending
- 2020-04-10 JP JP2021558700A patent/JP7577678B2/ja active Active
- 2020-04-10 KR KR1020217033598A patent/KR20210149747A/ko active Search and Examination
- 2020-04-10 WO PCT/CN2020/084247 patent/WO2020207477A1/zh active Application Filing
- 2020-04-13 TW TW109112352A patent/TW202104253A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3136163A1 (en) | 2020-10-15 |
KR20210149747A (ko) | 2021-12-09 |
JP7577678B2 (ja) | 2024-11-05 |
AU2020256648A1 (en) | 2021-11-04 |
WO2020207477A1 (zh) | 2020-10-15 |
JP2022527803A (ja) | 2022-06-06 |
EP3954701A4 (en) | 2023-09-06 |
US20220168396A1 (en) | 2022-06-02 |
EP3954701A1 (en) | 2022-02-16 |
CN112351994A (zh) | 2021-02-09 |
BR112021020071A2 (pt) | 2021-12-14 |
TW202104253A (zh) | 2021-02-01 |
WO2020207477A9 (zh) | 2020-11-26 |
CN112351994B (zh) | 2024-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012277A (es) | Agonista multireceptor y uso medico del mismo. | |
MY197569A (en) | Gip/glp1 co-agonist compounds | |
Prasad-Reddy et al. | A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond | |
Russell‐Jones et al. | Recent advances in incretin‐based therapies | |
Scott | Linagliptin: in type 2 diabetes mellitus | |
Bailey et al. | Treatment of type 2 diabetes: future approaches | |
MX2022014368A (es) | Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo. | |
Barnett et al. | Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy | |
Terauchi et al. | Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study | |
CN112512633A (zh) | 使用gip/glp1共激动剂用于治疗的方法 | |
MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
Waldrop et al. | Incretin-based therapy for diabetes: what a cardiologist needs to know | |
Unger | Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes | |
Cyganek et al. | Liraglutide therapy in Prader-Willi syndrome. | |
Pizzimenti et al. | Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. | |
PH12017501662A1 (en) | Treatment type 2 diabetes mellitus patients | |
JP2016522241A5 (es) | ||
Marroquin‐Harris et al. | Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists. | |
Engel et al. | Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin | |
Sheffield et al. | Off‐label use of exenatide for the management of insulin‐resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection | |
MX2023009550A (es) | Antagonistas del receptor del peptido-1 tipo glucagon. | |
Horowitz et al. | DPP-4 inhibition and the known unknown | |
Chaplin | DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes | |
Kenny et al. | GLP-1 receptor agonist and basal insulin co-therapy in type 2 diabetes: clinical evidence and practicalities of use | |
Chan et al. | Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know |